Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: Results from the open-label period of a phase II randomised controlled trial (faSScinate)

  • Dinesh Khanna*
  • , Christopher P. Denton
  • , Celia J.F. Lin
  • , Jacob M. Van Laar
  • , Tracy M. Frech
  • , Marina E. Anderson
  • , Murray Baron
  • , Lorinda Chung
  • , Gerhard Fierlbeck
  • , Santhanam Lakshminarayanan
  • , Yannick Allanore
  • , Janet E. Pope
  • , Gabriela Riemekasten
  • , Virginia Steen
  • , Ulf Müller-Ladner
  • , Helen Spotswood
  • , Laura Burke
  • , Jeffrey Siegel
  • , Angelika Jahreis
  • , Daniel E. Furst
  • *Korrespondierende/r Autor/-in für diese Arbeit
  • University of Michigan
  • University College London
  • Genentech Incorporated
  • Utrecht University
  • University of Utah
  • University of Liverpool
  • McGill University
  • Stanford University
  • Eberhard Karls Universität Tübingen
  • University of Connecticut Health Center
  • Universität Paris V
  • University of Western Ontario
  • Georgetown University
  • Justus-Liebig-Universität Gießen
  • Roche Products Ltd
  • University of California, Los Angeles

Abstract

Objectives: Assess the efficacy and safety of tocilizumab in patients with systemic sclerosis (SSc) in a phase II study. Methods: Patients with SSc were treated for 48 weeks in an open-label extension phase of the faSScinate study with weekly 162 mg subcutaneous tocilizumab. Exploratory end points included modified Rodnan Skin Score (mRSS) and per cent predicted forced vital capacity (%pFVC) through week 96. Results: Overall, 24/44 (55%) placebo-tocilizumab and 27/43 (63%) continuous-tocilizumab patients completed week 96. Observed mean (SD (95% CI)) change from baseline in mRSS was -3.1 (6.3 (-5.4 to -0.9)) for placebo and -5.6 (9.1 (-8.9 to-2.4)) for tocilizumab at week 48 and -9.4 (5.6 (-8.9 to -2.4)) for placebo-tocilizumab and -9.1 (8.7 (-12.5 to -5.6)) for continuous-tocilizumab at week 96. Of patients who completed week 96, any decline in %pFVC was observed for 10/24 (42% (95% CI 22% to 63%)) placebotocilizumab and 12/26 (46% (95% CI 27% to 67%)) continuous-tocilizumab patients in the open-label period; no patients had >10% absolute decline in %pFVC. Serious infection rates/100 patient-years (95% CI) were 10.9 (3.0 to 27.9) with placebo and 34.8 (18.0 to 60.8) with tocilizumab during the double-blind period by week 48 and 19.6 (7.2 to 42.7) with placebo-tocilizumab and 0.0 (0.0 to 12.2) with continuous-tocilizumab during the open-label period. Conclusions: Skin score improvement and FVC stabilisation in the double-blind period were observed in placebo-treated patients who transitioned to tocilizumab and were maintained in the open-label period. Safety data indicated increased serious infections in patients with SSc but no new safety signals with tocilizumab.

OriginalspracheEnglisch
ZeitschriftAnnals of the Rheumatic Diseases
Jahrgang77
Ausgabenummer2
Seiten (von - bis)212-220
Seitenumfang9
ISSN0003-4967
DOIs
PublikationsstatusVeröffentlicht - 02.2018

Fördermittel

Funding this study was funded by roche. Funding for manuscript preparation was provided by F Hoffmann-La roche Ltd.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

  1. SDG 3 – Gesundheit und Wohlergehen
    SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

  • Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: Results from the open-label period of a phase II randomised controlled trial (faSScinate)“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren